Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium

Blood Cancer Journal

Volumn 1, Issue 3, 2011, Pages

  Tefferi, A ^a   Abdel Wahab, O ^b   Ervantes, F C ^c   Crispino, J D ^d   Finazzi, G ^e   Girodon, F ^f   Gisslinger, H ^g   Gotlib, J ^h   Kiladjian, J J ⁱ   Levine, R L ^b   Licht, J D ^d   Mullally, A ^j   Odenike, O ^k   Pardanani, A ^a   Silver, R T ^l   Solary, E ^m   Mughal, T ⁿ  

^a MAYO CLINIC   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF BARCELONA   (Spain)

^d NORTHWESTERN UNIVERSITY   (United States)

^e OSPEDALI RIUNITI   (Italy)

^f HÔPITAL DU BOCAGE   (France)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ SAINT LOUIS HOSPITAL   (France)

^j BRIGHAM AND WOMEN S HOSPITAL   (United States)

^k UNIVERSITY OF CHICAGO   (United States)

^l WEILL CORNELL MEDICAL COLLEGE   (United States)

^m Universite Paris Sud   (France)

ⁿ GUY S HOSPITAL   (United Kingdom)

more..

Author keywords

Mastocytosis; Myelofibrosis; Myeloproliferative; Polycythemia; Thrombocythemia

Indexed keywords

ADDITIONAL SEX COMB LIKE1 PROTEIN; ALPHA INTERFERON; BUSULFAN; CLADRIBINE; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; EVEROLIMUS; HYDROXYUREA; ISOCITRATE DEHYDROGENASE; MIDOSTAURIN; MOMELOTINIB; PIPOBROMAN; POMALIDOMIDE; PROTEIN; RUXOLITINIB; TET ONCOGENE FAMILY MEMBER 2 PROTEIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANEMIA; ASCITES; CANCER PROGNOSIS; CANCER SURVIVAL; CONFERENCE PAPER; COUGHING; DIARRHEA; DIZZINESS; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; EPIGENETICS; FATIGUE; GENE MUTATION; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOTENSION; LEUKOCYTOSIS; LEUKOPENIA; LIVER FUNCTION TEST; LOW DRUG DOSE; LYMPHADENOPATHY; MASTOCYTOSIS; MOUTH ULCER; MULTIPLE CYCLE TREATMENT; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; NAUSEA; NEUROPATHY; NEUTROPENIA; OPPORTUNISTIC INFECTION; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHLEBOTOMY; PLEURA EFFUSION; POLYCYTHEMIA VERA; PRURITUS; PSYCHOPATHY; SCORING SYSTEM; SIDE EFFECT; SPLENOMEGALY; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOCYTOPENIA; THROMBOCYTOSIS; THROMBOSIS; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; URTICARIA PIGMENTOSA; VOMITING; WEIGHT REDUCTION;

EID: 84859306234     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2011.4     Document Type: Conference Paper

References (146)

1. Swerdlow SH CE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2008.
2. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-951.
3. Tefferi A. The history of myeloproliferative disorders: before and after Dameshek. Leukemia 2008; 22: 3-13.
4. Fialkow PJ, Gartler SM, Yoshida A. Clonal origin of chronic myelocytic leukemia in man. Proc Natl Acad Sci USA 1967; 58: 1468-1471.
5. Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann L. Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med 1976; 295: 913-916.
6. Jacobson RJ, Salo A, Fialkow PJ. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 1978; 51: 189-194. (Pubitemid 8284647)
7. Fialkow PJ, Faguet GB, Jacobson RJ, Vaidya K, Murphy S. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood 1981; 58: 916-919. (Pubitemid 12227928)
8. Martin PJ, Najfeld V, Hansen JA, Penfold GK, Jacobson RJ, Fialkow PJ. Involvement of the B-lymphoid system in chronic myelogenous leukaemia. Nature 1980; 287: 49-50. (Pubitemid 10018206)
9. Raskind WH, Jacobson R, Murphy S, Adamson JW, Fialkow PJ. Evidence for the involvement of B lymphoid cells in polycythemia vera and essential thrombocythemia. J Clin Invest 1985; 75: 1388-1390. (Pubitemid 15087170)
10. Reeder TL, Bailey RJ, Dewald GW, Tefferi A. Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia. Blood 2003; 101: 1981-1983. (Pubitemid 36237603)
11. Tefferi A, Schad CR, Pruthi RK, Ahmann GJ, Spurbeck JL, Dewald GW. Fluorescent in situ hybridization studies of lymphocytes and neutrophils in chronic granulocytic leukemia. Cancer Genet Cytogenet 1995; 83: 61-64.
12. Buschle M, Janssen JW, Drexler H, Lyons J, Anger B, Bartram CR. Evidence for pluripotent stem cell origin of idiopathic myelofibrosis: clonal analysis of a case characterized by a N-ras gene mutation. Leukemia 1988; 2: 658-660.
13. Lambert JR, Everington T, Linch DC, Gale RE. In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm. Blood 2009; 114: 3018-3023.
14. Landgren O, Goldin LR, Kristinsson SY, Helgadottir EA, Samuelsson J, Bjorkholm M. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24, 577 first-degree relatives of 11, 039 patients with myeloproliferative neoplasms in Sweden. Blood 2008; 112: 2199-2204.
15. Guglielmelli P, Biamonte F, Spolverini A, Pieri L, Isgro A, Antonioli E et al. Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. Leukemia 2010; 24: 1533-1537.
16. Jones AV, Campbell PJ, Beer PA, Schnittger S, Vannucchi AM, Zoi K et al. The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. Blood 2010; 115: 4517-4523.
17. Patnaik MM, Lasho TL, Finke CM, Gangat N, Caramazza D, Siragusa S et al. MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms. Leukemia 2010; 24: 859-860.
18. Tefferi A, Lasho TL, Patnaik MM, Finke CM, Hussein K, Hogan WJ et al. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia 2010; 24: 105-109.
19. Pardanani A, Lasho TL, Finke CM, Gangat N, Wolanskyj AP, Hanson CA et al. The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients. Leukemia 2010; 24: 110-114.
20. Olcaydu D, Rumi E, Harutyunyan A, Passamonti F, Pietra D, Pascutto C et al. The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. Haematologica 2010 (in press).
21. Haeno H, Levine RL, Gilliland DG, Michor F. A progenitor cell origin of myeloid malignancies. Proc Natl Acad Sci USA 2009; 106: 16616-16621.
22. James C, Mazurier F, Dupont S, Chaligne R, Lamrissi-Garcia I, Tulliez M et al. The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity. Blood 2008; 112: 2429-2438.
23. Pardanani A, Lasho TL, Finke C, Mesa RA, Hogan WJ, Ketterling RP et al. Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes. Stem Cells 2007; 25: 2358-2362. (Pubitemid 47480495)
24. Pardanani A, Lasho TL, Finke C, Markovic SN, Tefferi A. Demonstration of MPLW515K, but not JAK2V617F, in in vitro expanded CD4+ T lymphocytes. Leukemia 2007; 21: 2206-2207. (Pubitemid 47430454)
25. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360: 2289-2301.
26. Gelsi-Boyer V, Trouplin V, Adelaide J, Bonansea J, Cervera N, Carbuccia N et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009; 145: 788-800.
27. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148. (Pubitemid 40663494)
28. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790. (Pubitemid 40570926)
29. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-397. (Pubitemid 40544655)
30. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061. (Pubitemid 40386783)
31. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356: 459-468. (Pubitemid 46193073)
32. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3: e270.
33. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108: 3472-3476.
34. Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, McGuire C et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 2009; 113: 6182-6192.
35. Tefferi A, Lasho TL, Abdel-Wahab O, Guglielmelli P, Patel J, Caramazza D et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic-or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010; 24: 1302-1309.
36. Pardanani A, Lasho TL, Finke CM, Mai M, McClure RF, Tefferi A. IDH1 and IDH2 mutation analysis in chronic-and blast-phase myeloproliferative neoplasms. Leukemia 2010; 24: 1146-1151.
37. Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 2010; 362: 369-370.
38. Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao J, Hedvat C et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 2010; 70: 447-452.
39. Abdel-Wahab O, Pardanani A, Patel J, Lasho T, Heguy A, Levine R et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blastphase myeloproliferative neoplasms. ASH Annu Meet Abstr 2010; 116: 3070.
40. Jager R, Gisslinger H, Passamonti F, Rumi E, Berg T, Gisslinger B et al. Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. Leukemia 2010; 24: 1290-1298.
41. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42: 722-726.
42. Oh ST, Simonds EF, Jones C, Hale MB, Goltsev Y, Gibbs Jr KD et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 2010; 116: 988-992.
43. Bersenev A, Wu C, Balcerek J, Jing J, Kundu M, Blobel GA et al. Lnk constrains myeloproliferative diseases in mice. J Clin Invest 2010; 120: 2058-2069.
44. Rinaldi CR, Rinaldi P, Alagia A, Gemei M, Esposito N, Formiggini F et al. Preferential nuclear accumulation of JAK2V617F in CD34+ but not in granulocytic, megakaryocytic, or erythroid cells of patients with Philadelphia-negative myeloproliferative neoplasia. Blood 2010; 116: 6023-6026.
45. Dawson MA, Bannister AJ, Gottgens B, Foster SD, Bartke T, Green AR et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 2009; 461: 819-822.
46. Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009; 23: 905-911.
47. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 2008; 22: 1299-1307.
48. Hussein K, Abdel-Wahab O, Lasho TL, Van Dyke DL, Levine RL, Hanson CA et al. Cytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms. Am J Hematol 2010; 85: 81-83.
49. Nguyen-Khac F, Lesty C, Eclache V, Couronne L, Kosmider O, Andrieux J et al. Chromosomal abnormalities in transformed Phnegative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutations. Genes Chromosomes Cancer 2010; 49: 919-927.
50. Couronne L, Lippert E, Andrieux J, Kosmider O, Radford-Weiss I, Penther D et al. Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias. Leukemia 2010; 24: 201-203.
51. Tefferi A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Patnaik MM et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/ MPN and AML. Leukemia 2009; 23: 1343-1345.
52. Tefferi A, Levine RL, Lim KH, Abdel-Wahab O, Lasho TL, Patel J et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009; 23: 900-904.
53. Schaub FX, Looser R, Li S, Hao-Shen H, Lehmann T, Tichelli A et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood 2010; 115: 2003-2007.
54. Beer PA, Delhommeau F, LeCouedic JP, Dawson MA, Chen E, Bareford D et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 2010; 115: 2891-2900.
55. Kosmider O, Gelsi-Boyer V, Slama L, Dreyfus F, Beyne-Rauzy O, Quesnel B et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/ myeloproliferative neoplasms. Leukemia 2010; 24: 1094-1096.
56. Kohlmann A, Grossmann V, Klein HU, Schindela S, Weiss T, Kazak B et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol 2010; 28: 3858-3865.
57. Nibourel O, Kosmider O, Cheok M, Boissel N, Renneville A, Philippe N et al. Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood 2010; 116: 1132-1135.
58. Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009; 41: 838-842.
59. Flach J, Dicker F, Schnittger S, Kohlmann A, Haferlach T, Haferlach C. Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis. Haematologica 2010; 95: 518-519.
60. Paulsson K, Haferlach C, Fonatsch C, Hagemeijer A, Andersen MK, Slovak ML et al. The idic(X)(q13) in myeloid malignancies: breakpoint clustering in segmental duplications and association with TET2 mutations. Hum Mol Genet 2010; 19: 1507-1514.
61. Smith AE, Mohamedali AM, Kulasekararaj A, Lim Z, Gaken J, Lea NC et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 2010; 116: 3923-3932.
62. Kosmider O, Gelsi-Boyer V, Cheok M, Grabar S, Della-Valle V, Picard F et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 2009; 114: 3285-3291.
63. Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009; 114: 144-147.
64. Gaidzik VI, Schlenk RF, Paschka P, Kohne C-H, Held G, Habdank M et al. TET2 mutations in acute myeloid leukemia (AML): results on 783 patients treated within the AML HD98A Study of the AML Study Group (AMLSG). ASH Annu Meet Abstr 2010; 116: 97.
65. Metzeler KH, Maharry K, Radmacher MD, Mrozek K, Margeson D, Becker H et al. Mutations in the TET oncogene family member (TET2) gene refine the new European leukemia net risk classification of primary, cytogenetically normal acute myeloid leukemia (CN-AML) in adults: a Cancer and Leukemia Group B (CALGB) Study. ASH Annu Meet Abstr 2010; 116: 98.
66. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009; 324: 930-935.
67. Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010; 468: 839-843.
68. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18: 553-567.
69. Fisher CL, Pineault N, Brookes C, Helgason CD, Ohta H, Bodner C et al. Loss-of-function additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. Blood 2010; 115: 38-46.
70. Lee SW, Cho YS, Na JM, Park UH, Kang M, Kim EJ et al. ASXL1 represses retinoic acid receptor-mediated transcription through associating with HP1 and LSD1. J Biol Chem 2010; 285: 18-29.
71. Cho YS, Kim EJ, Park UH, Sin HS, Um SJ. Additional sex comblike (ASXL1), in cooperation with SRC-1, acts as a liganddependent coactivator for retinoic acid receptor. J Biol Chem 2006; 281: 17588-17598.
72. Carbuccia N, Murati A, Trouplin V, Brecqueville M, Adelaide J, Rey J et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 2009; 23: 2183-2186.
73. Carbuccia N, Trouplin V, Gelsi-Boyer V, Murati A, Rocquain J, Adelaide J et al. Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Leukemia 2010; 24: 469-473.
74. Boultwood J, Perry J, Pellagatti A, Fernandez-Mercado M, Fernandez-Santamaria C, Calasanz MJ et al. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia 2010; 24: 1062-1065.
75. Boultwood J, Perry J, Zaman R, Fernandez-Santamaria C, Littlewood T, Kusec R et al. High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression. Leukemia 2010; 24: 1139-1145.
76. Chou WC, Huang HH, Hou HA, Chen CY, Tang JL, Yao M et al. Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood 2010; 116: 4086-4094.
77. Gelsi-Boyer V, Trouplin V, Roquain J, Adelaide J, Carbuccia N, Esterni B et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol 2010; 151: 365-375.
78. Abdel-Wahab O, Kilpivaara O, Patel J, Busque L, Levine RL. The most commonly reported variant in ASXL1 (c.1934dupG;p.-Gly646TrpfsX12) is not a somatic alteration. Leukemia 2010; 24: 1656-1657.
79. Stein BL, Williams DM, McDevitt MA, O'Keefe CL, Rogers O, Spivak JL et al. Disruption of the ASXL1 gene is prevalent in PMF: analysis of molecular genetics and clinical phenotypes. ASH Annu Meet Abstr 2010; 116: 3074.
80. Fernandez-Mercado M, Pellagatti A, Perry J, Fernandez-Santamaria C, Calasanz MJ, Larrayoz MJ et al. Frequent mutation of the polycomb-associated gene ASXL1 in acute myeloid leukemia secondary to myelodysplastic syndrome or chronic myelomonocytic leukemia. ASH Annu Meet Abstr 116: 2940.
81. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010; 17: 225-234.
82. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2010; 465: 966.
83. Kranendijk M, Struys EA, van Schaftingen E, Gibson KM, Kanhai WA, van der Knaap MS et al. IDH2 mutations in patients with D-2-hydroxyglutaric aciduria. Science 2010, 330-336.
84. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807-1812.
85. Chou WC, Lei WC, Ko BS, Hou HA, Chen CY, Tang JL et al. The prognostic impact and stability of isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. Leukemia 2011; 25: 246-253.
86. Caramazza D, Lasho TL, Finke CM, Gangat N, Dingli D, Knudson RA et al. IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia. Leukemia 2010; 24: 2120-2122.
87. Patel JP, Abdel-Wahab O, Gonen M, Figueroa ME, Fernandez HF, Sun Z et al. High-throughput mutational profiling in AML: mutational analysis of the ECOG E1900 trial. ASH Annu Meet Abstr 2010; 116: 851.
88. Green CL, Evans CM, Hills RK, Burnett AK, Linch DC, Gale RE. The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood 2010; 116: 2779-2782.
89. Boissel N, Nibourel O, Renneville A, Gardin C, Reman O, Contentin N et al. Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol 2010; 28: 3717-3723.
90. Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Kronke J, Bullinger L et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010; 28: 3636-3643.
91. Pardanani A, Patnaik MM, Lasho TL, Mai M, Knudson RA, Finke C et al. Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q). Leukemia 2010; 24: 1370-1372.
92. Patnaik MM, Lasho TL, Finke CM, Gangat N, Caramazza D, Holtan SG et al. WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. Leukemia 2010; 24: 1283-1289.
93. Martinez-Garcia E, Licht JD. Deregulation of H3K27 methylation in cancer. Nat Genet 2010; 42: 100-101.
94. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010; 42: 181-185.
95. Yap DB, Chu J, Berg T, Schapira M, Cheng SWG, Moradian A et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 2011 blood-2010-2011-321208 (in press).
96. Sneeringer CJ, Scott MP, Kuntz KW, Knutson SK, Pollock RM, Richon VM et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci USA 107, 20980-20985.
97. Nikoloski G, Langemeijer SM, Kuiper RP, Knops R, Massop M, Tonnissen ER et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010; 42: 665-667.
98. Makishima H, Jankowska AM, Tiu RV, Szpurka H, Sugimoto Y, Hu Z et al. Novel homo-and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia 2010; 24: 1799-1804.
99. Stegelmann F, Schlenk RF, Griesshammer M, Paschka P, Blersch C, Kuhn S et al. Mutations of EZH2 In myeloproliferative neoplasms with myelofibrosis: correlation with molecular and clinical data. ASH Annu Meet Abstr 116: 4111.
100. Agger K, Cloos PA, Christensen J, Pasini D, Rose S, Rappsilber J et al. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature 2007; 449: 731-734. (Pubitemid 47552088)
101. van Haaften G, Dalgliesh GL, Davies H, Chen L, Bignell G, Greenman C et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet 2009; 41: 521-523.
102. Szpurka H, Jankowska AM, Przychodzen B, Hu Z, Saunthararajah Y, McDevitt MA et al. UTX mutations and epigenetic changes in MDS/MPN and related myeloid malignancies. ASH Annu Meet Abstr 116: 121.
103. Jankowska A, Makishima H, Tiu RV, Szpurka H, Huang Y, Sugimoto Y et al. Mutational spectrum in chronic myelomonocytic leukemia includes genes associated with epigenetic regulation such as UTX and EZH2. ASH Annu Meet Abstr 116, 611.
104. Kvasnicka HM, Thiele J. Prodromal myeloproliferative neoplasms: the 2008 WHO classification. Am J Hematol 2010; 85: 62-69.
105. Thiele J, Kvasnicka HM, Vardiman J. Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl. Best Pract Res Clin Haematol 2006; 19: 413-437. (Pubitemid 43884244)
106. Thiele J, Kvasnicka HM, Vardiman JW, Orazi A, Franco V, Gisslinger H et al. Bone marrow fibrosis and diagnosis of essential thrombocythemia. J Clin Oncol 2009; 27: e220-e221; author reply e222-223.
107. Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M et al. Survival and risk of leukemic transformation in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study on 1, 104 patients. ASH Annu Meet Abstr 2010; 116: 457.
108. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14-22.
109. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113: 2895-2901.
110. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115: 1703-1708.
111. Gangat N, Caramazza D, Vaidya R, George G, Begna KH, Schwager SM et al. DIPSS-Plus: A Refined Dynamic International Prognostic Scoring System (DIPSS) for Primary Myelofibrosis that Incorporates Prognostic Information from Karyotype, Platelet Count and Transfusion Status. J Clin Oncol 2011; 29: 392-397.
112. Caramazza D, Begna KH, Gangat N, Vaidya R, Siragusa S, Van Dyke DLet al. Refined cytogenetic risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia 2011; 25: 82-88.
113. Tefferi A, Mesa RA, Pardanani A, Hussein K, Schwager S, Hanson CA et al. Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not. Am J Hematol 2009; 84: 265-267.
114. Tefferi A, Siragusa S, Hussein K, Schwager SM, Hanson CA, Pardanani A et al. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis-prognostic relevance is independent of IPSS or karyotype. Am J Hematol 2009; 85: 14-17.
115. Patnaik MM, Caramazza D, Gangat N, Hanson CA, Pardanani A, Tefferi A. Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival. Eur J Haematol 2010; 84: 105-108.
116. Tefferi A, Lasho TL, Huang J, Finke C, Mesa RA, Li CY et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008; 22: 756-761. (Pubitemid 351559282)
117. Guglielmelli P, Barosi G, Specchia G, Rambaldi A, Lo Coco F, Antonioli E et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 2009; 114: 1477-1483.
118. Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A, Tefferi A. Circulating IL-2R, IL-8, IL-15 and CXCL10 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. ASH Annu Meet Abstr 2010; 116: 3068.
119. Pardanani A, George G, Lasho T, Hogan WJ, Litzow MR, Begna K et al. A phase I/II study of CYT387, an oral JAK-1/2 inhibitor, in myelofibrosis: significant response rates in anemia, splenomegaly, and constitutional symptoms. ASH Annu Meet Abst 2010; 116: 460
120. Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen PJ, Levy R et al. Durable responses with the JAK1/JAK2 inhibitor, INCB018424, in patients with polycythemia vera (PV) and essential thrombocythemia (ET) refractory or intolerant to hydroxyurea (HU). ASH Annu Meet Abst 2010; 116: 313.
121. Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 2009; 27: 4563-4569.
122. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010; 363: 1117-1127.
123. Pardanani A, Gotlib JR, Jamieson C, Cortes J, Talpaz M, Stone RM et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2010 (in press).
124. Quintas-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009; 27: 5418-5424.
125. Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008; 112: 3065-3072.
126. Shvidel L, Sigler E, Haran M, Klepfish A, Duek A, Berrebi A et al. Busulphan is safe and efficient treatment in elderly patients with essential thrombocythemia. Leukemia 2007; 21: 2071-2072. (Pubitemid 47299992)
127. Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. Leukemia and Hematosarcoma' Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.). Br J Cancer 1981 44:75-80.
128. Passamonti F, Brusamolino E, Lazzarino M, Barate C, Klersy C, Orlandi E et al. Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients. Haematologica 2000; 85: 1011-1018.
129. Petti MC, Spadea A, Avvisati G, Spadea T, Latagliata R, Montefusco E et al. Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991). Leukemia 1998; 12: 869-874. (Pubitemid 28287208)
130. De Sanctis V, Mazzucconi MG, Spadea A, Alfo M, Mancini M, Bizzoni L et al. Long-term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman: occurrence of leukaemic evolution. Br J Haematol 2003; 123: 517-521. (Pubitemid 37363498)
131. Passamonti F, Rumi E, Malabarba L, Arcaini L, Orlandi E, Brusamolino E et al. Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. Ann Hematol 2004; 83: 495-497. (Pubitemid 39144749)
132. Gangat N, Wolanskyj AP, McClure RF, Li CY, Schwager S, WuW et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia 2007; 21: 270-276. (Pubitemid 46158119)
133. Gangat N, Strand J, Li CY, Wu W, Pardanani A, Tefferi A. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol 2007; 138: 354-358. (Pubitemid 47035399)
134. Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C et al. Acute leukemia in polycythemia vera. An analysis of 1, 638 patients enrolled in a prospective observational study. Blood 2005; 105: 2664-2670. (Pubitemid 40446255)
135. Messinezy M, Pearson TC, Prochazka A, Wetherley-Mein G. Treatment of primary proliferative polycythaemia by venesection and low dose busulphan: retrospective study from one centre. Br J Haematol 1985; 61: 657-666. (Pubitemid 16231518)
136. Begna KH, Mesa RA, Pardanani A, Hogan WJ, Litzow MR, McClure RF et al. A phase-2 trial of low-dose pomalidomide in myelofibrosis with anemia. Leukemia 2011; 25: 301-304.
137. Vannucchi AM, Guglielmelli P, Lupo L, Finazzi MC, Tozzi L, Biamonte F et al. A phase 1/2 study of RAD001, a mTOR inhibitor, in patients with myelofibrosis: final results. ASH Annu Meet Abst 2010; 116: 314.
138. Fiskus W, Manepalli RR, Balusu R, Bhalla KN. Synergistic activity of combinations of JAK2 kinase inhibitor with PI3K/mTOR, MEK or PIM kinase inhibitor against human myeloproliferative neoplasm cells expressing JAK2V617F. ASH Annu Meet Abstr 2010; 116: 798.
139. Vannucchi AM, Bogani C, Bartalucci N, Guglielmelli P, Tozzi L, Antonioli E et al. The mTOR inhibitor, RAD001, inhibits the growth of cells from patients with myeloproliferative neoplasms. ASH Annu Meet Abstr 2009; 114: 2914.
140. Gotlib J, DeAngelo DJ, George TI, Corless CL, Linder A, Langford C et al. KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: report of a fully accrued phase II trial. ASH Annu Meet Abstr 2010; 116: 316.
141. Hermine O, Hirsh I, Damaj G, Granpeix C, Barete S, Suarez F et al. long term efficacy and safety of cladribine in adult systemic mastocytosis: a French Multicenter STUDY of 44 patients. ASH Annu Meet Abstr 2010; 116: 1982.
142. Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, Van't Wout JW, Verhoef G, Gerrits WB et al. Cladribine therapy for systemic mastocytosis. Blood 2003; 102: 4270-4276. (Pubitemid 37494083)
143. Lim KH, Pardanani A, Butterfield JH, Li CY, Tefferi A. Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol 2009; 84: 790-794.
144. Penack O, Sotlar K, Noack F, Horny HP, Thiel E, Notter M. Cladribine therapy in a patient with an aleukemic subvariant of mast cell leukemia. Ann Hematol 2005; 84: 692-693. (Pubitemid 41554248)
145. Quintas-Cardama A, Levine R, Manshouri T, Kilpivaara O, Kantarjian HM, Verstovsek S. High rates of molecular response after long-term follow-up of patients with advanced essential thrombocythemia (ET) or polycythemia vera (PV) treated with pegylated interferon-ALFA-2A (PEG-IFN-{alpha}-2A; PEGASYS). ASH Annu Meet Abstr 2010; 116: 461.
146. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010; 24: 1128-1138.